In vivo Evaluation of Tazarotene Solid Lipid Nanoparticles Gel For Topical Delivery
Journal Title: International Journal of Pharmaceutical Sciences and Drug Research - Year 2019, Vol 11, Issue 1
Abstract
The purpose of this research work was to develop and optimize the Solid Lipid Nanoparticles (SLNs) of Tazarotene for the effective topical delivery in the treatment of psoriasis. Tazarotene loaded SLNs were prepared by hot homogenization followed by the ultrasonication using Taguchi’s design and based on the results further investigation was made using central composite design. The lipid Dynasan-116, surfactant poloxomer-188 and co surfactant egg lecithin resulted in better percent drug loading and evaluated for particle size, zeta potential, TEM, drug entrapment efficiency, in vitro drug release and stability. All parameters were found to be in an acceptable range. In vitro drug release of optimized SLN formulation (F1) was found to be 98.12 ± 1.52%, whereas pure drug release was 42.12 after 60 min. The optimized formulation was incorporated into the gel. The release rate (flux) of tazarotene across the membrane and excised skin differs significantly. The accumulative amount of Tazarotene in skin from SLN based gel formulation and marketed gel were 41.12 ± 0.12 mg and 30.02 ± 0.04 mg respectively. This result supported our hypothesis made in skin permeation studies on rat skin. From histopathological studies the microscopic observations indicate that the optimized SLN formulation, SLN based gel formulation and marketed gel has no significant effect on the microscopic structure of the skin. The skin-irritation studies indicated that SLN based gel containing Tazarotene did not show any sign of skin irritation as compared to moderate erythema shown by marketed gel formulation (Tazret® gel) after 72 h of application. Thus, SLN based gel formulation demonstrated advantage over marketed formulation in improving the skin tolerability of Tazarotene indicating their potential in improving patient acceptance and topical delivery of Tazarotene.
Authors and Affiliations
Rajkumar Aland, M. Ganesan, P. Rajeswara Rao
Keywords
Related Articles
- EP ID EP446016
- DOI 10.25004/IJPSDR.2019.110107
- Views 107
- Downloads 0
DESIGN OF EXTENDED RELEASE MATRIX TABLET OF TRAMADOL HYDROCHLORIDE USING COMBINATION OF HYDROPHOBIC AND HYDROPHILIC POLYMER
The aim of design of oral extended drug delivery system is to achieve a prolonged therapeutic effect by continuously releasing medicament over an extended period of time after administration of a single dose. An attempt...
IN-VITRO ANTIBACTERIAL EFFICACY OF SOLVENT EXTRACTS OF LEAVES OF BAUHINIA RACEMOSA LAM. (CAESALPINIACEAE) AGAINST ENTERIC BACTERIAL PATHOGENS
Phytochemical screening of the plant leaves reveals the presence of carbohydrates, alkaloids, flavonoids, steroids, and tannins. Petroleum ether extract, chloroform extract, ethyl acetate extract and methanol extracts of...
GARCINIA LANCEIFOLIA ROXB; AN ENDEMIC MEDICINAL PLANT OF ASSAM RELIEVES PAIN AND DELAYS NOCICEPTIVE RESPONSE: AN ASSAY FOR ITS ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY
The stem bark of Garcinia lanceifolia, a lesser known species of the genus Garcinia, was extracted with methanol after pretreatment with petroleum ether. The resultant extract was evaluated for its analgesic and anti-inf...
FORMULATION AND OPTIMIZATION OF RAFT FORMING CHEWABLE TABLET CONTAINING LAFUTIDINE
Lafutidine is a new histamine H2- receptor antagonist having biological half-life of 1.92 h. Due to its selective absorption from upper part of gastrointestinal tract the gastroretentive drug delivery is desired in order...
SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM OF CANDESARTAN CILEXETIL WITH IMPROVED BIOAVAILABILITY
Candesartan is an angiotensin II receptor blocker with inherent low bioavailability. The present studies entail the optimization and evaluation of self- nanoemulsifying drug delivery system (SNEDDS) of Candesartan in ord...